CGH has received a 2024 Impact Factor of 12.0! On behalf of Editor-in-Chief Charles Kahi, thank you to our editors, authors, reviewers, and readers for your continued support. ow.ly/j03050We50o#GITwitter#LiverTwitter@JosephHabibi_MD
Study finds carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis. Check out the full article here: ow.ly/oWNm50PCBoQ
February Editor's Essential Reading examines rare, overlooked, and underappreciated causes of recurrent abdominal pain. Learn more at ow.ly/wXHa50MAqsU
Great news! Clinical Gastroenterology and Hepatology, AGA’s clinically focused journal, reached a record-high 2020 Impact Factor of 11.382, pulling ahead as the field’s top exclusively clinically oriented journal!
We’re excited to announce the release of our supplement on Hepatic Encephalopathy! This is a collaboration with @JHospMedicine. Thanks to @JasmohanBajaj for chairing this program and to Salix Pharmaceuticals for their support ow.ly/w3he50KeR7A
Combining vedolizumab or ustekinumab with an immunomodulator is no more effective than monotherapy in induction or maintenance of remission in patients with IBD: ow.ly/K7A150EjWC2